Clearmind Medicine Inc(CMND) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -705.15 | Insider Own | 0.04% | Shs Outstand | 0.3M | Perf Week | -21.03% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.1M | Perf Month | -26.54% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | - | Inst Own | 10.83% | Short Float | 1.93% | Perf Quarter | -68.95% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 0.53% | Short Ratio | 0.02 | Perf Half Y | -89.07% |
| Sales | 0.00B | P/B | 0.1 | EPS next 5Y | - | ROA | -71.81% | Short Interest | 0.00M | Perf YTD | -96.81% |
| Book/sh | 48.3 | P/C | 0.15 | EPS past 3/5Y | 83.49% 39.75% | ROE | -106.98% | 52W High | -99.78% ($2076.80) | Perf Year | -99.53% |
| Cash/sh | 31.42 | P/FCF | - | Sales past 3/5Y | - | ROIC | -57.44% | 52W Low | -6.29% ($4.93) | Perf 3Y | -99.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 74.01% | Gross Margin | - | Volatility(W/M) | 8.61% 6.5% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.48 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.31 | EPS Q/Q | 99.42% | Profit Margin | - | RSI (14) | 24.79 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.31 | Sales Q/Q | - | SMA20 | -20.33% ($5.8) | Beta | -1.11 | Target Price | - |
| Payout | - | Debt/Eq | 0.14 | Earnings | - | SMA50 | -29.01% ($6.51) | Rel Volume | 0.19 | Prev Close | $4.95 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | - | SMA200 | -88.06% ($38.69) | Avg Volume(3M) | 0.06M | Price | $4.62 |
| IPO | 2021/8/16 | Option/Short | No/Yes | Trades | 180 | Volume | 10,554 | Change | -6.67% |
🧠 Neuropsychiatric biopharmaceutical company. Developing psychedelic-based therapeutics. CMND-100 for the treatment of alcohol use disorder. Phase 1/2a clinical trials currently underway. Holds 19 international patents.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded less than usual. That is 19% of its average volume.
CMND has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF <0.01% It ranks #569 of 597 in the industry
Based on market cap of $2M.
EOCN#566 Eocene Ltd $2M PER - 
JUNS#567 Jupiter Neurosciences Inc $2M PER - 
CLDI#568 Calidi Biotherapeutics Inc $2M PER - CMND#569 Clearmind Medicine Inc $2M PER - 
VIVS#570 VivoSim Labs Inc $2M PER - 
FAQ
What kind of company is CMND?
CMND belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CMND?
The market cap of CMND is approximately $2M, ranking 5,760 within its sector.
What is the 52-week high and low for CMND?
CMND has recorded a 52-week high of $2076.80 and a low of $4.93.
